Elite Pharmaceuticals, Inc.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Elite Pharmaceuticals reports stellar Q1 results and eyes growth opportunities

Elite Pharmaceuticals delivered robust Q1 2025 results, showcasing significant revenue and income growth, improved cash flow, and strong financial health. Strategic investments and operational focus contributed to the company's success.
With a solid cash position, working capital, and proactive growth initiatives, Elite Pharmaceuticals is well-positioned to capitalize on market opportunities, drive innovation, and maintain compliance and operational excellence.
While challenges in sustaining growth and navigating regulatory requirements exist, Elite Pharmaceuticals' focus on strategic planning, financial discipline, and market expansion presents promising opportunities for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elite Pharmaceuticals, Inc. engages in the provision of development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications and New Drug Applications segments. The ANDA segment includes generic pharmaceuticals. The NDA segment is composed of branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.

Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Hydrocodone and acetaminophen is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets

Precipio

Here we highlight a small cap and a microcap with Zacks Outperform ratings.

Two Smaller Companies Worthy of Your "Attention"

ELTP sees strong revenue growth despite a net loss, driven by new product launches and strategic acquisitions.

Elite Pharmaceuticals' Stock Up Despite Q2 Earnings Decline

Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2025 Earnings Conference Call November 15, 2024 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Carter Ward - CFO Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2025 Conference Call. At this time all lines have been placed on a listen-only mode.

Elite Pharmaceuticals, Inc. (ELTP) Q2 2025 Earnings Conference Call Transcript

Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's fiscal year ending on March 31, 2025 ("Second Quarter"). Consolidated revenues for the three months ended September 30, 2024, were $18.9 million, an increase of $4.7 million or approximately 33% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live conference call on Friday, November 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced the Israeli Ministry of Health approval for Elite's generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 10 mg, 20 mg, and 30 mg tablets. Elite will supply the product to Dexcel Pharma (Or Akiva, Israel), the Company's exclusive distributor, for the Israeli market.

Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health

Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets. Acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate.

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets

Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic methotrexate sodium 2.5 mg tablets. Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen, mycosis fungoides, relapsed or refractory non-Hodgkin's lymphoma as part of a metronomic combination regimen, rheumatoid arthritis and severe psoriasis Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) and acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen This product is marketed and sold under the Elite Laboratories, Inc. label.

Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium

Strength in Elite Pharmaceuticals' (ELTP) Manufacturing fees drive its fiscal first-quarter performance.

Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q1 2025 Earnings Conference Call August 15, 2024 11:30 AM ET Company Participants Nasrat Hakim – President and Chief Executive Officer Carter Ward – Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals First Quarter of Fiscal Year 2025 Conference Call. At this time, all lines have been placed on a listen-only mode.

Elite Pharmaceuticals, Inc. (ELTP) Q1 2025 Earnings Call Transcript

Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended June 30, 2024, which is the first quarter of the Company's fiscal year ending on March 31, 2025 ("First Quarter"). Consolidated revenues for the three-month period ended June 30, 2024, were $18.8 million, an increase of $9.8 million or approximately 109% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information

Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024 Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2025 fiscal year will be released on Wednesday, August 14, 2024. Elite's management will host a live conference call on Thursday, August 15th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024

Discover why Zacks rates Elite Pharmaceuticals as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore ELTP's strategic partnerships, financial health, and robust product pipeline.

Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q4 2024 Earnings Conference Call July 2, 2024 11:30 AM ET Company Participants Nasrat Hakim - President and CEO Carter Ward - CFO, Secretary and Treasurer Conference Call Participants Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Conference Call. At this time, all lines have been placed on a listen-only mode.

Elite Pharmaceuticals, Inc. (ELTP) Q4 2024 Earnings Call Transcript

Elite Pharmaceuticals' (ELTP) overall top line benefits from revenue growth in Manufacturing fees.

Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2024 ("Fiscal 2024"). Consolidated revenues for Fiscal 2024 were $56.6 million, an increase of $22.4 million or approximately 65% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Acacia Research

Barfresh Food Group

Butler National Corporation

Fortitude Gold Corp

Lesaka Technologies Inc

To find the best undiscovered penny stocks, first take a look at the over-the-counter (OTC) market. Why? Many of the best bargains among penny stocks, or stocks trading for $5 per share or less, can be found among equities that trade OTC.

Treasure Hunt: 7 Penny Stocks Wall Street Hasn't Discovered Yet

Financials for Fiscal Year 2024 Ended March 31, 2024 will be released on July 1, 2024 Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2024 fiscal year-end financial results on Monday, July 1, 2024. Elite's management will host a live conference call on Tuesday, July 2nd, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update.

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024

Broadwind Energy

E2open Parent Holdings

New Gold

Pitney Bowes

There are thousands of U.S.-listed stocks categorized as penny stocks, or stocks trading for $5 per share or less but only a few can be considered strong buy penny stocks. “Penny stock territory” contains a lot of busted growth stories, fallen angels and value traps, yet dive deep enough into the space, and you'll find plenty of asymmetric opportunities.

7 Strong Buy Penny Stocks to Buy Now: June 2024

NORTHVALE, NJ / ACCESSWIRE / May 20, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for generic Methotrexate Sodium 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label.

Elite Pharmaceuticals Receives FDA Approval for Generic Methotrexate

Elite Pharmaceuticals, Inc. (ELTP) Q3 2024 Earnings Call Transcript

Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the third quarter of fiscal year 2024 ended December 31, 2023 ("Third Quarter"). Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year.

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Financials for Third Quarter Fiscal Year 2024 Ended December 31, 2023 will be released on February 14, 2024 NORTHVALE, NJ / ACCESSWIRE / February 8, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2024 fiscal year will be released on Wednesday, February 14, 2024. Elite's management will host a live conference call on Thursday, February 15th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update.

News for Elite Pharmaceuticals, Inc. Stock (ELTP)